AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04921579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-Step retraction
Description: Retraction of canine started on a 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 150 g per side) followed by anterior teeth retraction on 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 160 g per side) extending between crimpable hooks and the mini-screw.
Study NCT05005702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle training
Description: Patients received IMT for 30-minute per day, 3 days per week for 3 weeks using the Threshold Inspiratory Muscle training device (product Phillips). During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training.~Inspiratory muscle training diaries were checked weekly. The inspiratory load was set at 40%of maximal inspiratory pressure.
Study NCT04513093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy Massage
Description: The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.
Study NCT00866489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote preconditioning
Description: Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
Study NCT01551368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
Study NCT01551368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical inactive tablets.
Study NCT02928705 — intervention group
Intervention type: PROCEDURE
Intervention: physician operated telemedical prehospital analgesia
Description: Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
Study NCT02928705 — intervention group
Intervention type: PROCEDURE
Intervention: prehospital analgesia by on-scene EMS physicians
Description: This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
Study NCT05109767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The Virtual Reality Glass game application reduces anxiety by distracting attention..The virtual reality glass game was played to intervention group for 15 minutes before surgery.
Study NCT05109767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: The Smartphone game application reduces anxiety by distracting attention. Smartphone game was played to intervention group for 15 minutes before surgery.
Study NCT03202680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USDA Style Diet
Description: USDA style healthy diet, low in saturated fats.
Study NCT03202680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean Beef Diet
Description: A lean beef containing healthy diet, low in saturated fats.
Study NCT01731964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telescope prosthesis
Description: Monocular implantation of the telescope prosthesis after cataract extraction
Study NCT01731964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WA-NG Telescope Prothesis
Description: The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
Study NCT03435042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self care + Hypnosis group
Description: Our groupal intervention is divided into 6 monthly 2-hour sessions in which some self-hypnosis exercises are proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
Study NCT00368875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00368875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00368875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT02847481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: fecal microbiota transplantation
Study NCT02847481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo fecal microbiota transplantation
Description: placebo fecal microbiota transplantation
Study NCT02847481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT with antibiotic pre-treatment (v1)
Description: FMT with antibiotic pre-treatment (v1)
Study NCT02847481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT with antibiotic pre-treatment (v2)
Description: FMT with antibiotic pre-treatment (v2)
Study NCT04240249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constructive self-assertiveness program via the internet
Description: Participants will get one chapter a week to work with. All chapters are presented on web pages and include information and exercises and end with homework assignments.
Study NCT01282515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate 0,05% ointment
Description: continuously daily treatment for 6 weeks
Study NCT01282515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hexaminolevulinate
Description: one PDT treatment
Study NCT04633850 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: Intravenous dexamethasone 8 mg. Given once at the end of surgery.
Study NCT04633850 — intervention group
Intervention type: DRUG
Intervention: Bupivacain
Description: Bupivacaine dose according to weight. \<60 kg: Total dose 100mg 60-90kg: Total dose 150mg >90kg: Total dose 200mg~Given once at the end of surgery.
Study NCT02842437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
Study NCT02842437 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive matching placebo (equal volume of normal saline)
Study NCT00607581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide: 500 mg orally on days 1, 8, 15
Study NCT00607581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: lenalidomide: 15 mg orally on days 1-21
Study NCT00607581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
Study NCT04049305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional nipple sparing mastectomy (C-NSM)
Description: Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
Study NCT04049305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic assisted nipple sparing mastectomy (E-NSM)
Description: E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
Study NCT04207580 — intervention group
Intervention type: OTHER
Intervention: Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,
Description: The study consists in collecting clinical, biological, psychological and social data of INS pediatric patients.~A bio collection is also created: blood, urine, hair and nails will be collected at the beginning of the INS (before starting immunosuppressive treatment).
Study NCT00749229 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: balloon kyphoplasty
Description: During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
Study NCT03874923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid challenge
Description: After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
Study NCT03874923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Description: After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
Study NCT00636935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics only
Description: Antibiotic only for treatment for mild (pO2 > 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
Study NCT00636935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics + Corticosteroids
Description: Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
Study NCT00636935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids + antibiotics
Description: Drugs will be prescribed per standard of care for patients with PCP and pO2 \< 70mmHg.
Study NCT04313257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monocular Active Occlusion
Description: Occlusion treatment of one hour daily with action video game.
Study NCT04313257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monocular Passive Occlusion
Description: Occlusion treatment of two hour daily.
Study NCT01299480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
Study NCT01299480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
Study NCT01299480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
Study NCT01299480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: rLP2086 at visits 1 and 3, saline at visits 2 and 5
Study NCT01299480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: rLP2086 at visits 3 and 5, saline at visits 1 and 2
Study NCT02380053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: 2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
Study NCT02380053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celiprolol
Description: 2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
Study NCT00617929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
Study NCT00617929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: administered 375 mg/m\^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
Study NCT00617929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: administered 30 mg/m\^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
Study NCT00617929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: administered on Day 0 per institutional guidelines.
Study NCT00047255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins.
Study NCT00047255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins.
Study NCT00047255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes.
Study NCT00047255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuxumab
Description: Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes.
Study NCT00047255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins.
Study NCT03326362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Comparison between high and low intensities trainings described in arms
Study NCT03326362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Comparison between high and low intensities trainings described in arms
Study NCT00832468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ear acupressure
Description: The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
Study NCT00832468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham ear acupressure
Description: The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
Study NCT03838523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Label Placebo
Description: See group description
Study NCT01838954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-wave diathermy
Description: Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
Study NCT04135612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone based communication
Description: Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles.
Study NCT01046006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Rituximab, Dexamethasone
Description: Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv
Study NCT00597142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Express™ Renal Premounted Stent System
Description: This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:~* Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery~* Lesion length ≤15mm~* Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen~* RVD 4.0-7.0mm